BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Corus Pharma, Inc. Release: Aztreonam Data To Be Presented At European Cystic Fibrosis Society Conference


10/19/2005 5:08:55 PM

SEATTLE, June 15 /PRNewswire/ -- Dr. Jane L. Burns will present Corus Pharma's Aztreonam Lysinate for Inhalation (AI) clinical Phase 2 microbiology results at the European Cystic Fibrosis Society Conference (ECFS) in Crete on Friday, June 24, 2005 at 5:00 p.m. EEST (Eastern European Summer Time) as part of a session on antibiotics and resistance.

WHO: Dr. Jane L. Burns and Corus Pharma WHAT: Presentation of Corus Pharma's Aztreonam Lysinate for Inhalation (AI) clinical Phase 2 microbiology results. WHEN: Friday, June 24, 2005 at 5:00 p.m. WHERE: Creta Maris, Crete (Athena room) About The Phase 2 Results

The Phase 2 study was comprised of 105 cystic fibrosis (CF) patients with pulmonary Pseudomonas aeruginosa infections. It evaluated two dose groups (75 mg and 225 mg) with twice daily applications for two weeks in a double blinded, placebo-controlled trial.

Both dose levels were well tolerated with similar adverse event profiles as the placebo, though the 225 mg dose had a trend to increased respiratory symptoms (most commonly cough) when compared to either the 75 mg dose or placebo. There were no serious adverse events reported as related to AI.

There was a significant decrease in the amount of Pseudomonas aeruginosa as measured by sputum density with both dose groups showing greater than or equal to 97% reduction (greater than or equal to 1.5 log) from baseline (p < 0.001). In patients with abnormal lung function at baseline, there was a significant improvement in FEV1 measured over the duration of the study (p < 0.05).

Based on the Phase 2 results, Corus is currently enrolling patients in the AIR-CF Phase 3 clinical trials and more information can be found at www.AIR-CF.com. AI is delivered by the eFlow(R) Electronic Nebulizer developed by PARI GmbH with an average treatment time in Corus' Phase 2 clinical trial of 2.4 minutes for the 75mg dose.

About Dr. Jane L. Burns

Jane L. Burns, MD, is a Professor of Pediatrics at the University of Washington in Seattle, Washington. She is also Director of the Cystic Fibrosis Microbiology Laboratory and the Infectious Disease Clinic at Children's Hospital and Regional Medical Center, also in Seattle. Dr. Burns earned her medical degree from the University of Washington.

About Corus Pharma

Corus Pharma is committed to developing and commercializing products for severe respiratory and infectious diseases that can help provide improved health and quality of life. More information about Corus Pharma may be found at www.coruspharma.com.

Corus Pharma

CONTACT: Jonathan Mow of Corus Pharma, +1-206-792-3020, orjmow@coruspharma.com; or Leslie Cohan of Dave Syferd & Partners,+1-206-262-0395, or cell, +1-206-849-1810, or lcohan@dsandp.com, for CorusPharma



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES